#1 Clinical Trials Search in Europe

Octocog Alfa

This article summarizes key findings from clinical trials investigating the use of octocog alfa, also known as ReFacto AF, for treating hemophilia A. The trials examined the drug’s safety, efficacy, pharmacokinetics, and patient-reported outcomes in both adults and children with severe or moderately severe hemophilia A.

Table of Contents

What is Octocog Alfa?

Octocog alfa is a type of medicine known as a recombinant factor VIII (rFVIII) concentrate. It is a man-made version of the blood clotting protein factor VIII, which is missing or doesn’t work properly in people with hemophilia A. Octocog alfa is used to treat and prevent bleeding in patients with this condition[1][2].

Brand Names

Octocog alfa is marketed under several brand names, including:

  • Advate
  • ReFacto
  • ReFacto AF
  • Xyntha
  • Helixate
  • Kogenate

These different brand names may refer to slightly different formulations or manufacturing processes, but they all contain octocog alfa as the active ingredient[3][4].

What is it Used For?

Octocog alfa is primarily used to treat and prevent bleeding in people with hemophilia A. Hemophilia A is an inherited disorder where the blood doesn’t clot properly due to a lack of functioning factor VIII. This can lead to:

  • Spontaneous bleeding (bleeding that occurs without an obvious cause)
  • Prolonged bleeding after injuries or surgeries
  • Bleeding into joints, which can cause pain and damage over time

Octocog alfa can be used in different ways, including:[1][2]

  • On-demand therapy: to treat bleeding episodes when they occur
  • Prophylaxis: regular treatments to prevent bleeding episodes
  • Perioperative management: to prevent excessive bleeding during and after surgeries

How it Works

When you have a cut or injury, your body normally forms a blood clot to stop the bleeding. This process involves several steps and requires specific proteins called clotting factors. In hemophilia A, factor VIII is missing or doesn’t work properly, which disrupts the clotting process.

Octocog alfa works by replacing the missing or defective factor VIII in your body. When injected into the bloodstream, it helps your blood form clots normally, stopping or preventing bleeding episodes[1].

Administration

Octocog alfa is given as an intravenous (IV) injection, which means it’s injected directly into a vein. The dose and frequency of treatment can vary depending on several factors, including:

  • The severity of your hemophilia
  • Your body weight
  • The purpose of treatment (on-demand, prophylaxis, or surgery)
  • The specific product being used

Your doctor will determine the appropriate dosing schedule for you. Some patients or their caregivers may be trained to administer the medication at home[3].

Efficacy

Clinical studies have shown that octocog alfa is effective in treating and preventing bleeding episodes in patients with hemophilia A. Some key findings include:

  • Reduction in the number of bleeding episodes when used for prophylaxis
  • Effective control of bleeding when used for on-demand treatment
  • Successful management of bleeding during surgical procedures

The effectiveness can be measured by factors such as the number of infusions needed to treat a bleed, the response to treatment, and the annual bleeding rate[1][4].

Safety and Side Effects

Octocog alfa is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include:

  • Headache
  • Fever
  • Cough
  • Nausea or vomiting
  • Joint pain
  • Reactions at the injection site (redness, swelling, or itching)

A more serious but rare side effect is the development of inhibitors. Inhibitors are antibodies that your immune system may produce against the factor VIII, making the treatment less effective. Your doctor will monitor you for inhibitor development[4][5].

Pharmacokinetics

Pharmacokinetics refers to how the body processes a drug. For octocog alfa, important pharmacokinetic parameters include:

  • Half-life: The time it takes for half of the drug to be eliminated from your body
  • Clearance: How quickly your body removes the drug
  • Recovery: How much the factor VIII level in your blood increases after an injection

These parameters can vary between individuals and may be influenced by factors such as age and body weight. Understanding these parameters helps doctors determine the most appropriate dosing regimen for each patient[6][7].

Quality of Life

Treatment with octocog alfa can significantly improve the quality of life for people with hemophilia A. Benefits may include:

  • Fewer bleeding episodes, leading to less pain and joint damage
  • Increased ability to participate in physical activities
  • Fewer hospital visits and days missed from work or school
  • Greater independence in managing the condition

Studies have used various questionnaires to assess how treatment affects patients’ physical functioning, emotional well-being, and overall satisfaction with their care[2].

Aspect Findings
Safety Generally well-tolerated; adverse events and inhibitor development monitored
Efficacy Effective in preventing and treating bleeding episodes; reduced annualized bleeding rates
Pharmacokinetics Comparable bioavailability between different formulations; individual dosing based on pharmacokinetic data explored
Quality of Life Improvements in health-related quality of life and physical functioning reported
Patient Satisfaction High levels of satisfaction with treatment handling and efficacy reported by patients and caregivers
Dosing Strategies Weight-based dosing and pharmacokinetic-guided dosing investigated for optimizing treatment

FAQ

  • What is octocog alfa (ReFacto AF)? Octocog alfa, marketed as ReFacto AF, is a recombinant factor VIII product used to treat and prevent bleeding in people with hemophilia A. It is a manufactured version of the clotting factor that is missing or deficient in those with hemophilia A.
  • How is ReFacto AF administered? ReFacto AF is administered intravenously (into a vein). The dosage and frequency of administration depend on the individual patient's needs, severity of hemophilia, and whether it's being used for treatment or prevention of bleeding.
  • What were the main outcomes measured in the ReFacto AF clinical trials? The trials measured various outcomes including pharmacokinetics (how the drug moves through the body), safety (adverse events), efficacy in preventing and treating bleeds, quality of life, and patient/caregiver satisfaction with treatment.
  • Were there any significant safety concerns identified in the trials? While adverse events were monitored, no major safety concerns were highlighted in the trial summaries. The most significant potential risk with factor VIII products is the development of inhibitors, which was assessed in some of the studies.
  • How effective was ReFacto AF in preventing and treating bleeds? The trials indicated that ReFacto AF was effective in both preventing and treating bleeding episodes in patients with hemophilia A. Specific efficacy measures included annualized bleeding rates and the number of infusions needed to control bleeding episodes.

Ongoing Clinical Trials on Octocog Alfa

  • Study on the Safety and Effectiveness of Emicizumab for Patients with Type 3 Von Willebrand Disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +2

  • Study on Preventing Bleeding in Children with Severe von Willebrand Disease Using Vonicog Alfa and Octocog Alfa

    Recruiting

    3 1 1 1
    Investigated drugs:
    France Ireland Italy Spain

  • Study on the Effectiveness and Safety of Vonicog Alfa with or without Octocog Alfa for Children with Severe von Willebrand Disease Experiencing Bleeding or Undergoing Surgery

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium France Italy Spain

Glossary

  • Hemophilia A: An inherited bleeding disorder caused by a deficiency in clotting factor VIII, leading to impaired blood clotting and increased risk of bleeding.
  • Factor VIII (FVIII): A protein in the blood that is essential for normal blood clotting. People with hemophilia A have low levels or dysfunctional factor VIII.
  • Recombinant factor VIII: A manufactured version of factor VIII produced using genetic engineering techniques, rather than derived from human blood.
  • Prophylaxis: Regular treatment to prevent bleeding episodes in people with hemophilia.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Annualized Bleeding Rate (ABR): The average number of bleeding episodes a person with hemophilia experiences in a year.
  • Inhibitors: Antibodies that the immune system develops against factor VIII, making treatment less effective or ineffective.
  • Health-related Quality of Life (HRQoL): A measure of a person's perceived physical and mental health over time.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT01790828
  2. https://clinicaltrials.gov/study/NCT02718677
  3. https://clinicaltrials.gov/study/NCT02586012
  4. https://clinicaltrials.gov/study/NCT00895037
  5. https://clinicaltrials.gov/study/NCT00195442
  6. https://clinicaltrials.gov/study/NCT01579903
  7. https://clinicaltrials.gov/study/NCT03006965